Traws remedies control weaknesses, raises $10M as FDA halts lead drug; cash at $3.1M

Filed May 15, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 15, 2025 · ~1 min read

Key Changes

• high

  FDA placed tivoxavir marboxil on clinical hold due to toxicology data concerns, blocking US trials for the lead virology asset until resolved; company targets end-2026 but timeline uncertain.

  MD&A: FDA clinical hold verify on EDGAR →
• high

  Cash fell to $3.1M at March 31, 2026 from $15.9M prior year; April financing provided $10M upfront but company states this is insufficient for 12 months, maintaining going-concern doubt.

  MD&A: Cash position verify on EDGAR →
• high

  Material weaknesses in internal controls remediated; disclosure controls now effective as of March 31, 2026 versus ineffective March 31, 2025.

  Controls and Procedures verify on EDGAR →